Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Apr 27, 2023; 15(4): 664-673
Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.664
Table 1 Patients general data
Characteristic
Value
Sex (female/male), n3/21
Age (yr), mean ± SD51.3 ± 9.7
Height (cm), mean ± SD168.7 ± 6.1
Weight (kg), mean ± SD63.4 ± 12.5
Previous episodes of variceal bleeding, mean ± SD3 ± 2
Treatment history, n (%)
β blockade only2 (8.3)
Sclera therapy only4 (16.7)
β blockade and sclerotherapy18 (75.0)
Child-Pugh stage, n (%)
A5 (20.8)
B18 (75.0)
C1 (4.2)
Ascites, n (%)
None16 (66.7)
Mild2 (8.3)
Severe6 (25.0)
HVPG in mmHg, n (%)
< 1011 (45.8)
≥ 1013 (54.2)
Table 2 Perfusion computed tomography parameters changes before and after transjugular intrahepatic portosystemic shunt
Parameters
Before TIPS
After TIPS
P value
Liver parenchyma
LBF97.2 ± 32.285.8 ± 37.90.232
LBV19.2 ± 5.312.1 ± 2.4< 0.001
HAF (× 10-2)12.3 ± 6.155.3 ± 9.9< 0.001
Spleen parenchyma
SBF107.6 ± 32.1160.6 ± 33.1< 0.001
SBV12.1 ± 3.018.7 ± 3.4< 0.001
Table 3 Computed tomography perfusion comparisons between clinically significant portal hypertension and non-clinically significant portal hypertension before and after transjugular intrahepatic portosystemic shunt
Parameters
NCSPH (n = 11)
CSPH (n = 13)
P value
Before TIPS
Liver parenchyma
LBF103.6 ± 23.391.7 ± 38.30.377
LBV19.5 ± 2.918.9 ± 6.90.796
HAF (× 10-2)5.4 ± 2.818.2 ± 10.90.001
Spleen parenchyma
SBF95.9 ± 25.1117.4 ± 34.90.102
SBV12.4 ± 3.512.0 ± 2.70.747
After TIPS
Liver parenchyma
LBF77.5 ± 33.992.8 ± 41.00.336
LBV11.3 ± 2.412.7 ± 2.20.165
HAF (× 10-2)54.4 ± 11.456.0 ± 8.80.711
Spleen parenchyma
SBF150.0 ± 35.7169.9 ± 29.10.153
SBV19.2 ± 3.818.3 ± 3.00.522